查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134976

全球創傷性腦損傷治療產品線分析 - 2026 年（第二季洞察與臨床試驗）

Global Traumatic Brain Injury Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

創傷性腦損傷仍然是最難治療的神經系統疾病之一，因為目前的治療方法主要以緩解症狀為主，而非修復神經損傷。製藥公司正日益關注預防繼發性腦損傷、減輕神經發炎、促進神經再生以及改善認知和身體功能的長期恢復。生物標記、人工智慧、再生醫學和精準神經科學的進步，為創新藥物的研發創造了新的機會。

市場促進因素

全球創傷性腦損傷負擔日益加重

  • 交通事故、跌倒、運動傷害、軍事創傷和工傷等疾病的發生率不斷上升，導致需要有效治療性介入的患者人數日益增多。人們對長期神經系統疾病的認知不斷提高，也進一步推動了對創新療法的需求。

神經保護藥物研發進展

  • 研究日益關注繼發性損傷機制，例如氧化壓力、興奮性毒性、粒線體功能障礙、細胞凋亡和神經發炎。這些進展有助於開發旨在保護神經功能和改善神經功能恢復的療法。

加大對再生醫學的投資

  • 幹細胞療法、神經修復方法和再生醫學持續吸引大量投資，因為研發人員正在尋求不僅可以防止進一步損傷而且可以修復受損神經組織的治療方法。

改善臨床試驗基礎設施

  • 先進的神經影像學、血液生物標記、數位監測技術和精確的患者分層技術的應用，正在改進臨床試驗設計，並增強人們對未來療法開發的信心。

市場限制因素

複雜疾病的生物學特徵

  • 創傷性腦損傷在損傷嚴重程度、損傷機制和長期結果方面表現出顯著的生物學異質性，這使得治療方法的開發特別具有挑戰性。

臨床試驗失敗率高

  • 迄今為止進行的大量臨床試驗均未能證明其具有有意義的臨床療效，這增加了研發風險並延長了獲得監管部門批准的時間。

已通過核准藥物療法的供應有限

  • 目前，尚無廣泛認可的創傷性腦損傷緩解疾病藥物，這給藥物研發者帶來了重大的科學、監管和商業挑戰。

深入了解管道和技術

  • 全球創傷性腦損傷治療藥物研發管線可依研發階段、分子類型、治療方式、作用機轉、給藥途徑及地區分類。
  • 從研發階段來看，此研發管線涵蓋藥物發現、臨床前研究、I期臨床試驗、II期臨床試驗、III期臨床試驗、監理申報等項目。藥物發現和臨床前研究計畫佔比最大，研發人員持續探索與神經保護、神經再生、發炎控制和功能恢復相關的新型治療標靶。雖然已有多個候選藥物進入I期和II期臨床試驗階段，但進入後期研發階段的療法相對較少。
  • 依分子類型分類，研發管線涵蓋小分子化合物、生物製藥、幹細胞療法、再生醫學產品、胜肽療法和基因療法。由於小分子化合物具有生產優勢和完善的監管管道，它們在研發中仍然佔據主導地位，而再生醫學仍然是成長最快的創新領域之一。
  • 從治療類型來看，目前正在臨床實驗的療法包括神經保護劑、抗發炎劑、抗氧化療法、幹細胞療法、再生醫學、神經修復療法以及聯合治療。神經保護劑仍然是最大的研究領域之一，因為它們主要針對創傷後的繼發性神經細胞損傷。隨著神經發炎日益被認為是導致長期神經功能障礙的主要原因，抗發炎療法正在迅速發展。幹細胞療法因其再生能力而持續吸引研究人員的廣泛關注。
  • 從作用機轉來看，正在研發的候選藥物主要針對降低氧化壓力、調節細胞激素、保護粒線體、抑制細胞凋亡、促進神經再生、血管生成、修復突觸以及免疫調節。基於生物標記的精準醫療正日益推動更具標靶性的療法的研發。

開發平臺趨勢

  • 創傷性腦損傷的藥物研發趨勢正不斷轉向基於作用機制的療法。

主要趨勢如下：

  • 擴大神經保護藥物的研發。
  • 增加對再生醫學和幹細胞療法的投資。
  • 基於生物標記的患者選擇方法正在被擴大應用。
  • 擴大人工智慧在臨床開發的應用。
  • 精準神經學方法的拓展。
  • 擴大產學合作。
  • 針對多種損傷途徑的聯合治療研發正在取得進展。

區域趨勢

  • 北美憑藉其先進的創傷中心、強大的神經科學研究基礎設施、大量的生物技術投資以及完善的監管流程，仍然是創傷性腦損傷治療研發領域的領先地區。該地區在臨床創新和產品線拓展方面繼續發揮主導作用。
  • 歐洲透過擴大合作、推動再生醫學計畫、參與多國臨床試驗，不斷鞏固其在神經科學領域的地位。公共和私人投資持續支持神經系統藥物的研發。
  • 在亞太地區，由於生物技術能力的成長、臨床試驗基礎設施的改善、醫療保健領域投資的增加以及全球神經科學研究參與度的提高，預計研發管線將大幅擴展。
  • 在拉丁美洲、中東和非洲，隨著創傷治療基礎設施的改善和神經學研究計畫的擴展，參與國際臨床開發的機會正在逐漸增加。

競爭格局

  • 全球創傷性腦損傷治療研發管線涉及製藥公司、生技公司、再生醫學開發公司、學術研究機構和神經科學專家。
  • 各機構持續投資於神經保護劑、抗發炎療法、再生醫學、幹細胞技術、抗氧化療法和精準神經科學。策略聯盟、授權協議、臨床夥伴關係和研究合作仍然是加速藥物研發和商業化的關鍵。

未來展望

  • 未來，創傷性腦損傷治療的發展將日益側重於延緩疾病進展、促進神經細胞修復和改善長期神經功能恢復的療法。精準醫療、基於生物標記的治療選擇、再生醫學以及人工智慧驅動的臨床開發預計將在2035年前加速創新。
  • 神經科學研究的不斷進步、患者群體更精確的分類以及對神經系統疾病治療投入的增加，有望加強全球研發管線，豐富未來的治療選擇。

結論

  • 《全球創傷性腦損傷治療研發管線分析》展現了創新領域快速發展的態勢，這主要得益於神經保護療法、再生醫學、精準神經病學以及基於生物標記的藥物研發等領域的進步。儘管臨床複雜性和創紀錄的高失敗率仍然是重大挑戰，但持續的科學進步和合作有望為製藥公司、生物技術公司、研究人員、醫療保健專業人員和投資者創造大量機會。

本報告的主要益處

  • 對全球創傷性腦損傷治療藥物開發平臺進行全面分析。
  • 對處於臨床開發各階段的在臨床實驗藥物進行詳細評估。
  • 深入了解新的治療機制、研發管線創新和商業化機會。
  • 對策略聯盟、監管發展和未來發展趨勢進行競爭分析。
  • 這將成為製藥公司、生技公司、投資者、研究人員、顧問和醫療保健機構的寶貴資訊來源。

公司對我們報告的使用

  • 產品線基準分析、臨床開發規劃、競爭情報分析、許可和合作評估、投資分析、投資組合最佳化、監管策略制定、商業化規劃和長期策略決策。

調查範圍

  • 歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
  • 全球創傷性腦損傷治療藥物研發管線進行全面分析，依研發階段、分子類型、療法、作用機制、給藥途徑及地區分類。
  • 臨床實驗中療法的評估、臨床開發進展、研發管線成熟度、監管狀態和商業化機會。
  • 對策略聯盟、授權活動、競爭格局、創新趨勢和未來發展策略進行評估。
  • 對神經保護劑、抗發炎劑、抗氧化療法、幹細胞療法、再生醫學、神經修復療法、精準神經病學、基於生物標記的藥物開發以及到 2035 年的新治療機會進行分析。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：創傷性腦損傷病程的動態變化

  • 因素
  • 抑制因子
  • 潛在機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Neuren Pharmaceuticals
    • Supernus Pharmaceuticals
    • Vasopharm
    • NeuroTrauma Sciences
    • SanBio
  • 管線分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • 輕度腦外傷/腦震盪
    • 中度創傷性腦損傷
    • 嚴重創傷性腦損傷
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前已暫停招募參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 贊助商和合作研究者分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Neuren Pharmaceuticals
  • Supernus Pharmaceuticals
  • Vasopharm
  • NeuroTrauma Sciences
  • SanBio

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008984

Traumatic brain injury remains one of the most challenging neurological disorders because current treatment primarily consists of supportive care rather than therapies capable of repairing neurological damage. Drug developers are increasingly focusing on limiting secondary brain injury, reducing neuroinflammation, promoting neuroregeneration, and improving long-term cognitive and functional recovery. Advances in biomarkers, artificial intelligence, regenerative medicine, and precision neuroscience are creating new opportunities for innovative drug development.

Market Drivers

Increasing Global Burden of Traumatic Brain Injury

  • The growing incidence of road traffic accidents, falls, sports-related injuries, military trauma, and occupational accidents continues to expand the patient population requiring effective therapeutic intervention. Rising awareness of long-term neurological disability is further strengthening demand for innovative treatments.

Advances in Neuroprotective Drug Development

  • Research is increasingly targeting secondary injury mechanisms including oxidative stress, excitotoxicity, mitochondrial dysfunction, apoptosis, and neuroinflammation. These advances are supporting development of therapies designed to preserve neuronal function and improve neurological recovery.

Growing Investment in Regenerative Medicine

  • Stem cell therapies, neurorestorative approaches, and regenerative medicine continue attracting significant investment as developers pursue therapies capable of repairing damaged neural tissue rather than only preventing further injury.

Improving Clinical Trial Infrastructure

  • The use of advanced neuroimaging, blood biomarkers, digital monitoring technologies, and precision patient stratification is improving clinical trial design and increasing confidence in future therapeutic development.

Market Restraints

Complex Disease Biology

  • Traumatic brain injury presents substantial biological heterogeneity across injury severity, injury mechanisms, and long-term outcomes, making therapeutic development particularly challenging.

High Clinical Failure Rates

  • Numerous historical clinical trials have failed to demonstrate meaningful clinical benefit, increasing development risk and extending regulatory timelines.

Limited Approved Pharmacological Therapies

  • No widely accepted disease-modifying drug currently exists for traumatic brain injury, creating significant scientific, regulatory, and commercial challenges for developers.

Pipeline and Technology Insights

  • The global traumatic brain injury drug pipeline can be segmented by development stage, molecule type, therapeutic modality, mechanism of action, route of administration, and geography.
  • By development stage, the pipeline includes discovery, preclinical, Phase I, Phase II, Phase III, and registration-stage programs. Discovery and preclinical programs represent the largest segment because developers continue investigating novel therapeutic targets involved in neuroprotection, neuroregeneration, inflammation control, and functional recovery. Several candidates are advancing through Phase I and Phase II clinical studies, while relatively few therapies have progressed into late-stage development.
  • By molecule type, the pipeline includes small molecules, biologics, stem cell therapies, regenerative medicine products, peptide therapies, and gene-based approaches. Small molecules continue to dominate development because of their manufacturing advantages and established regulatory pathways, while regenerative medicine remains one of the fastest-growing innovation areas.
  • By therapeutic modality, investigational therapies include neuroprotective agents, anti-inflammatory agents, antioxidant therapies, stem cell therapies, regenerative medicine, neurorestorative therapies, and combination therapies. Neuroprotective agents remain one of the largest segments because they target secondary neuronal injury following trauma. Anti-inflammatory therapies are expanding rapidly as neuroinflammation becomes increasingly recognized as a major contributor to long-term neurological disability. Stem cell therapies continue attracting strong research interest because of their regenerative potential.
  • By mechanism of action, pipeline candidates target oxidative stress reduction, cytokine modulation, mitochondrial protection, apoptosis inhibition, neuroregeneration, angiogenesis, synaptic repair, and immune modulation. Biomarker-guided precision medicine is increasingly supporting more targeted therapeutic development.

Pipeline Trends

  • The traumatic brain injury drug development landscape continues shifting toward mechanism-based therapies.

Key trends include:

  • Expansion of neuroprotective drug development.
  • Growing investment in regenerative medicine and stem cell therapies.
  • Increasing use of biomarker-guided patient selection.
  • Greater adoption of artificial intelligence in clinical development.
  • Expansion of precision neurology approaches.
  • Growing academic-industry research collaborations.
  • Development of combination therapies targeting multiple injury pathways.

Regional Insights

  • North America remains the leading region for traumatic brain injury drug development because of advanced trauma centers, strong neuroscience research infrastructure, significant biotechnology investment, and supportive regulatory pathways. The region continues to lead clinical innovation and pipeline expansion.
  • Europe continues strengthening its position through collaborative neuroscience research, regenerative medicine programs, and increasing participation in multinational clinical trials. Public and private investment continues supporting neurological drug development.
  • Asia-Pacific is expected to experience substantial pipeline growth owing to expanding biotechnology capabilities, improving clinical trial infrastructure, increasing healthcare investment, and rising participation in global neurological research.
  • Latin America and the Middle East & Africa are gradually increasing participation in international clinical development through improving trauma care infrastructure and expanding neurological research programs.

Competitive Landscape

  • The global traumatic brain injury drug pipeline includes pharmaceutical companies, biotechnology firms, regenerative medicine developers, academic research organizations, and neuroscience specialists.
  • Organizations continue investing in neuroprotective agents, anti-inflammatory therapies, regenerative medicine, stem cell technologies, antioxidant therapies, and precision neurology. Strategic collaborations, licensing agreements, clinical partnerships, and research alliances remain central to accelerating drug development and commercialization.

Future Outlook

  • The future of traumatic brain injury drug development will increasingly focus on therapies capable of modifying disease progression, promoting neuronal repair, and improving long-term neurological recovery. Precision medicine, biomarker-guided treatment selection, regenerative medicine, and artificial intelligence-supported clinical development are expected to accelerate innovation through 2035.
  • Continued advances in neuroscience research, improved patient stratification, and increasing investment in neurological therapeutics are expected to strengthen the global pipeline and improve future treatment options.

Conclusion

  • The Global Traumatic Brain Injury Drug Pipeline Analysis demonstrates a rapidly expanding innovation landscape supported by advances in neuroprotective therapies, regenerative medicine, precision neurology, and biomarker-guided drug development. Although clinical complexity and historically high failure rates remain important challenges, continued scientific progress and collaborative research are expected to create significant opportunities for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, and investors.

Key Benefits of this Report

  • Comprehensive analysis of the global traumatic brain injury drug development pipeline.
  • Detailed evaluation of investigational drug candidates across all clinical development stages.
  • Insights into emerging therapeutic mechanisms, pipeline innovation, and commercialization opportunities.
  • Competitive assessment of strategic collaborations, regulatory progress, and future development trends.
  • Valuable resource for pharmaceutical companies, biotechnology firms, investors, researchers, consultants, and healthcare organizations.

What Businesses Use Our Reports For

  • Pipeline benchmarking, clinical development planning, competitive intelligence, licensing and partnership evaluation, investment analysis, portfolio optimization, regulatory strategy development, commercialization planning, and long-term strategic decision-making.

Report Coverage

  • Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global traumatic brain injury drug pipeline by development stage, molecule type, therapeutic modality, mechanism of action, route of administration, and geography
  • Evaluation of investigational therapies, clinical development progress, pipeline maturity, regulatory landscape, and commercialization opportunities
  • Assessment of strategic collaborations, licensing activities, competitive positioning, innovation trends, and future development strategies
  • Analysis of neuroprotective agents, anti-inflammatory agents, antioxidant therapies, stem cell therapies, regenerative medicine, neurorestorative therapies, precision neurology, biomarker-guided drug development, and emerging therapeutic opportunities through 2035.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. TRAUMATIC BRAIN INJURY PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Neuren Pharmaceuticals
    • 5.1.2. Supernus Pharmaceuticals
    • 5.1.3. Vasopharm
    • 5.1.4. NeuroTrauma Sciences
    • 5.1.5. SanBio
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. Mild TBI / Concussion
    • 5.4.2. Moderate TBI
    • 5.4.3. Severe TBI
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Neuren Pharmaceuticals
  • 6.2. Supernus Pharmaceuticals
  • 6.3. Vasopharm
  • 6.4. NeuroTrauma Sciences
  • 6.5. SanBio

7. LIST OF TABLES

8. LIST OF FIGURES